drug
SENS-601
Preclinicalupdated 3mo agoby Sensorion SA
Preclinicalcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
News(1)
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.biopharma_dive · 2mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that